What is the price of Lifitegrast (Xiidra) 5% solution in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Price of Lifitegrast 5% Solution (Xiidra) in India

Based on the most recent evidence from 2025, the price of Lifitegrast 5% ophthalmic solution (Xiidra) in India is not specifically documented in the available medical literature and guidelines.

While the price information for Lifitegrast 5% solution in India is not directly provided in the available evidence, we can note several important aspects about this medication:

About Lifitegrast 5% Solution (Xiidra)

  • Lifitegrast is a novel small molecule integrin antagonist that blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), which contributes to T-cell activation and migration in dry eye disease 1
  • It was FDA approved in 2016 for the treatment of signs and symptoms of dry eye disease 2
  • The medication is administered as eye drops twice daily 3

Clinical Efficacy in Indian Population

  • A recent 2025 randomized, double-blind, active-controlled trial in Indian patients with dry eye disease demonstrated significantly more favorable outcomes with lifitegrast 5% compared to carboxymethylcellulose 0.5% 3
  • The study showed improvements in eye dryness score, ocular discomfort score, ocular surface disease index, and tear film break-up time in Indian patients 3

Pricing Context

  • While the US pricing data is available in medical guidelines (ranging from $338-$1,283 for various medications in the same therapeutic categories), specific Indian pricing for Lifitegrast is not provided 4
  • Pharmaceutical pricing varies significantly between countries due to different regulatory frameworks, market conditions, and healthcare systems 4

Availability and Considerations

  • The medication has demonstrated efficacy in Indian patients with dry eye disease 3
  • Approximately 20.9% of dry eye disease patients receive lifitegrast treatment according to a survey of eyecare professionals in the USA and Canada 5
  • The medication is generally well tolerated with most adverse events being mild to moderate in severity 6

Clinical Outcomes

  • Treatment with lifitegrast has been associated with statistically significant improvements in matrix metalloproteinase-9 levels, ocular symptoms, corneal staining, and tear breakup time 7
  • Global improvement and tolerability were found to be better with lifitegrast compared to carboxymethylcellulose in Indian patients 3

To obtain current and accurate pricing information for Lifitegrast 5% solution in India, it would be advisable to contact local pharmacies, pharmaceutical distributors, or the manufacturer directly.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.